Edition:
United States

Amphastar Pharmaceuticals Inc (AMPH.OQ)

AMPH.OQ on NASDAQ Stock Exchange Global Select Market

17.74USD
19 Jul 2017
Change (% chg)

-- (--)
Prev Close
$17.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
143,810
52-wk High
$21.75
52-wk Low
$12.06

Latest Key Developments (Source: Significant Developments)

Amphastar Pharmaceuticals reports Q1 earnings per share $0.02
Monday, 8 May 2017 04:05pm EDT 

May 8 (Reuters) - Amphastar Pharmaceuticals Inc :Amphastar Pharmaceuticals reports financial results for the three months ended march 31, 2017.Q1 earnings per share $0.02.Q1 revenue $56.7 million versus I/B/E/S view $63.2 million.Q1 adjusted non-GAAP earnings per share $0.09.Q1 earnings per share view $0.07 -- Thomson Reuters I/B/E/S.Amphastar Pharmaceuticals - a decrease in production at ims facility resulted in a sales order backlog of approximately $8.0 million as of March 31, 2017.  Full Article

Amphastar Pharma Q4 gaap loss per share $0.06
Monday, 13 Mar 2017 04:21pm EDT 

Amphastar Pharmaceuticals Inc : Amphastar Pharmaceuticals reports financial results for the three months and fiscal year ended December 31, 2016 . Q4 gaap loss per share $0.06 . Q4 revenue $63.5 million versus I/B/E/S view $55.8 million . Q4 earnings per share view $-0.01 -- Thomson Reuters I/B/E/S .Q4 adjusted non-GAAP earnings per share $0.01.  Full Article

Momenta Pharmaceuticals says U.S. Court of Appeals reversed district court's dismissal filed by Amphastar Pharma against Co
Wednesday, 8 Mar 2017 09:01am EST 

Amphastar Pharmaceuticals Inc : Momenta Pharmaceuticals- on March 6, U.S. Court of Appeals for first circuit reversed district court's dismissal filed by Amphastar Pharma against Co .Momenta Pharmaceuticals- suit by Amphastar against Co alleged Momenta, Sandoz sought to prevent Amphastar from selling generic enoxaparin sodium injection.  Full Article

Amphastar announces the receipt of a CRL for Intranasal Naloxone for the emergency treatment of opioid overdose
Tuesday, 21 Feb 2017 06:00am EST 

Amphastar Pharmaceuticals Inc : Amphastar announces the receipt of a CRL for Intranasal Naloxone for the emergency treatment of opioid overdose . Amphastar Pharmaceuticals Inc - CRL identifies issues including user human factors study, device evaluation, and other items that need to be addressed .Amphastar Pharmaceuticals Inc - Will continue to offer Naloxone in pre-filled syringes while we pursue NDA for Intranasal Naloxone.  Full Article

Amphastar Pharmaceuticals receives Complete Response Letter
Tuesday, 27 Dec 2016 06:00am EST 

Amphastar Pharmaceuticals Inc : Amphastar Pharmaceuticals Inc - CRL indicated that armstrong should make further changes to label and packaging for Primatene Mist . Amphastar Pharma - intend to continue to work with fda to address their concerns in CRL by middle of 2017 and bring Primatene Mist back to OTC market . Amphastar Pharmaceuticals receives complete response letter for Primatene® Mist . Amphastar Pharmaceuticals Inc - Amphastar is evaluating content of letter and plans further discussions with FDA .Amphastar Pharma - CRL indicated that armstrong should conduct another human factor validation study.  Full Article

Amphastar Pharma Q2 adjusted non-gaap earnings per share $0.23
Monday, 8 Aug 2016 04:05pm EDT 

Amphastar Pharmaceuticals Inc : Q2 gaap earnings per share $0.15 . Q2 earnings per share view $0.01 -- Thomson Reuters I/B/E/S . Amphastar pharmaceuticals reports financial results for the three months ended june 30, 2016 . Q2 revenue $68 million versus i/b/e/s view $62.1 million .Q2 adjusted non-gaap earnings per share $0.23.  Full Article

Amphastar buys International Medication Systems(UK)for $7.7 mln
Thursday, 4 Aug 2016 06:00am EDT 

Amphastar Pharmaceuticals Inc : Purchases International Medication Systems (UK) Limited from UCB Pharma GMBH .Deal for $7.7 million.  Full Article

Amphastar Pharmaceuticals Q1 EPS $0.05
Monday, 9 May 2016 04:05pm EDT 

Amphastar Pharmaceuticals Inc : Amphastar pharmaceuticals reports financial results for the first quarter ended march 31, 2016 . Q1 earnings per share $0.05 . Q1 revenue $59.4 million versus i/b/e/s view $62 million . Q1 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S .Q1 adjusted non-gaap earnings per share $0.12.  Full Article

Momenta, Sandoz face off with Amphastar in blockbuster drug patent trial

Momenta Pharmaceuticals Inc and Novartis AG's Sandoz unit took Amphastar Pharmaceuticals Inc to trial Tuesday in a long-running suit over patent infringement that seeks hundreds of millions of dollars in damages over Amphastar's generic version of the blockbuster blood-thinner Lovenox.